Abstract
Since 1973 a number of investigators have reported an association between liver neoplasia and steroid usage. Through referral material we have examined the histology of over 250 cases of hepatic neoplasia, most in patients receiving steroid medications. The majority have been benign, predominantly focal nodular hyperplasia (55%) and hepatocellular adenoma (39%). The average age was 31.4 years; 83% had significant steroid exposure with an average duration of 71 months for focal nodular hyperplasia and 79.6 months for hepatocellular adenoma. The type of estrogenic agent was predominantly mestranol; however, during the period mestranol was the most frequently used synthetic steroid. A distinct clinical entity of life threatening hemorrhage from the lesion occurred in 31% of patients with hepatocellular adenoma and 9% of patients with focal nodular hyperplasia. Recurrence of benign tumors has occurred in some patients who continued using steroids and regression has been observed in patients who had incomplete tumor removal but discontinued steroid medication. Medial and intimal vascular changes have been present in a large number of the benign tumors. The relationship of these vascular changes to oncogenesis is unclear, but similar lesions have been described in the peripheral vasculature associated with steroid administration. A number of hepatocellular carcinomas have also been seen. Of significance is the young age of these patients and lack of abnormal histology in adjacent nonneoplastic liver. A striking number of the malignant hepatocellular tumors have been of the uncommon type described as "eosinophilic hepatocellular carcinoma with lamellar fibrosis." The epidemiology of liver lesions within this series is difficult to assess, since the material has been referred from very diverse locations.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baum J. K., Bookstein J. J., Holtz F., Klein E. W. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973 Oct 27;2(7835):926–929. doi: 10.1016/s0140-6736(73)92594-4. [DOI] [PubMed] [Google Scholar]
- Berman M. M., Libbey N. P., Foster J. H. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. 1980 Sep 15;46(6):1448–1455. doi: 10.1002/1097-0142(19800915)46:6<1448::aid-cncr2820460626>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- CAROLI J., PARAF A., CHARBONNIER A., VALLIN J. Implantations d'oestrogènes apparemment suivies d'un cancer primitif du foie. Rev Int Hepatol. 1953;3(4):497–510. [PubMed] [Google Scholar]
- Christopherson W. M., Mays E. T., Barrows G. H. Liver tumors in women on contraceptive steroids. Obstet Gynecol. 1975 Aug;46(2):221–223. [PubMed] [Google Scholar]
- Christopherson W. M., Mays E. T., Barrows G. Hepatocellular carcinoma in young women on oral contraceptives. Lancet. 1978 Jul 1;2(8079):38–39. doi: 10.1016/s0140-6736(78)91341-7. [DOI] [PubMed] [Google Scholar]
- Edmondson H. A., Henderson B., Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976 Feb 26;294(9):470–472. doi: 10.1056/NEJM197602262940904. [DOI] [PubMed] [Google Scholar]
- Edmondson H. A., Reynolds T. B., Henderson B., Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med. 1977 Feb;86(2):180–182. doi: 10.7326/0003-4819-86-2-180. [DOI] [PubMed] [Google Scholar]
- Horvath E., Kovacs K., Ross R. C. Ultrastructural findings in a well-differentiated hepatoma. Digestion. 1972;7(1):74–82. doi: 10.1159/000197263. [DOI] [PubMed] [Google Scholar]
- Irey N. S., Norris H. J. Intimal vascular lesions associated with female reproductive steroids. Arch Pathol. 1973 Oct;96(4):227–234. [PubMed] [Google Scholar]
- Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology. 1977 Aug;73(2):386–394. [PubMed] [Google Scholar]
- Malt R. A., Hershberg R. A., Miller W. L. Experience with benign tumors of the liver. Surg Gynecol Obstet. 1970 Feb;130(2):285–291. [PubMed] [Google Scholar]
- Motsay G. J., Gamble W. G. Clinical experience with hepatic adenomas. Surg Gynecol Obstet. 1972 Mar;134(3):415–418. [PubMed] [Google Scholar]
- Mulvihill J. J., Ridolfi R. L., Schultz F. R., Borzy M. S., Haughton P. B. Hepatic adenoma in Fanconi anemia treated with oxymetholone. J Pediatr. 1975 Jul;87(1):122–124. doi: 10.1016/s0022-3476(75)80087-4. [DOI] [PubMed] [Google Scholar]
- O'Sullivan J. P., Wilding R. P. Liver hamartomas in patients on oral contraceptives. Br Med J. 1974 Jul 6;3(5922):7–10. doi: 10.1136/bmj.3.5922.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Palmer P. E., Christopherson W. M., Wolfe H. J. Alpha1-antitrypsin, protein marker in oral contraceptive-associated hepatic tumors. Am J Clin Pathol. 1977 Dec;68(6):736–739. doi: 10.1093/ajcp/68.6.736. [DOI] [PubMed] [Google Scholar]
- Rooks J. B., Ory H. W., Ishak K. G., Strauss L. T., Greenspan J. R., Hill A. P., Tyler C. W., Jr Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979 Aug 17;242(7):644–648. [PubMed] [Google Scholar]
- Ross D., Pina J., Mirza M., Galvan A., Ponce L. Letter: Regression of focal nodular hyperplasia after discontinuation of oral contraceptives. Ann Intern Med. 1976 Aug;85(2):203–204. doi: 10.7326/0003-4819-85-2-203. [DOI] [PubMed] [Google Scholar]
- Sweeney E. C., Evans D. J. Letter: Liver lesions and androgenic steroid therapy. Lancet. 1975 Nov 22;2(7943):1042–1042. doi: 10.1016/s0140-6736(75)90332-3. [DOI] [PubMed] [Google Scholar]